BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34857661)

  • 1. Biodistribution and Radiation Dosimetry of Intraperitoneally Administered
    Grkovski M; Modak S; Zanzonico PB; Carrasquillo JA; Larson SM; Humm JL; Pandit-Taskar N
    J Nucl Med; 2022 Jul; 63(7):1094-1100. PubMed ID: 34857661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.
    Modak S; Zanzonico P; Grkovski M; Slotkin EK; Carrasquillo JA; Lyashchenko SK; Lewis JS; Cheung IY; Heaton T; LaQuaglia MP; Cheung NV; Pandit-Taskar N
    J Clin Oncol; 2020 Dec; 38(36):4283-4291. PubMed ID: 33119478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and Dosimetry of Intraventricularly Administered
    Pandit-Taskar N; Zanzonico PB; Kramer K; Grkovski M; Fung EK; Shi W; Zhang Z; Lyashchenko SK; Fung AM; Pentlow KS; Carrasquillo JA; Lewis JS; Larson SM; Cheung NV; Humm JL
    J Nucl Med; 2019 Dec; 60(12):1794-1801. PubMed ID: 31405921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunoscintigraphy and Pretreatment Dosimetry of
    Pandit-Taskar N; Grkovski M; Zanzonico PB; Pentlow KS; Modak S; Kramer K; Humm JL
    J Nucl Med; 2023 Jun; 64(6):946-950. PubMed ID: 36759197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
    Rizvi SN; Visser OJ; Vosjan MJ; van Lingen A; Hoekstra OS; Zijlstra JM; Huijgens PC; van Dongen GA; Lubberink M
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):512-20. PubMed ID: 22218876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study to assess safety, biodistribution and radiation dosimetry for
    Merkx RIJ; Lobeek D; Konijnenberg M; Jiménez-Franco LD; Kluge A; Oosterwijk E; Mulders PFA; Rijpkema M
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3277-3285. PubMed ID: 33651116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and Dosimetry of
    Pandit-Taskar N; Zanzonico P; Staton KD; Carrasquillo JA; Reidy-Lagunes D; Lyashchenko S; Burnazi E; Zhang H; Lewis JS; Blasberg R; Larson SM; Weber WA; Modak S
    J Nucl Med; 2018 Jan; 59(1):147-153. PubMed ID: 28705916
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase 1 study of intraventricular
    Kramer K; Pandit-Taskar N; Kushner BH; Zanzonico P; Humm JL; Tomlinson U; Donzelli M; Wolden SL; Haque S; Dunkel I; Souweidane MM; Greenfield JP; Tickoo S; Lewis JS; Lyashchenko SK; Carrasquillo JA; Chu B; Horan C; Larson SM; Cheung NV; Modak S
    J Hematol Oncol; 2022 Nov; 15(1):165. PubMed ID: 36371226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study.
    Bretin F; Bahri MA; Bernard C; Warnock G; Aerts J; Mestdagh N; Buchanan T; Otoul C; Koestler F; Mievis F; Giacomelli F; Degueldre C; Hustinx R; Luxen A; Seret A; Plenevaux A; Salmon E
    Mol Imaging Biol; 2015 Aug; 17(4):557-64. PubMed ID: 25595813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
    Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
    J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
    Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
    J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.
    Doss M; Kolb HC; Zhang JJ; Bélanger MJ; Stubbs JB; Stabin MG; Hostetler ED; Alpaugh RK; von Mehren M; Walsh JC; Haka M; Mocharla VP; Yu JQ
    J Nucl Med; 2012 May; 53(5):787-95. PubMed ID: 22499613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers.
    Doss M; Kolb HC; Walsh JC; Mocharla V; Fan H; Chaudhary A; Zhu Z; Alpaugh RK; Lango MN; Yu JQ
    J Nucl Med; 2013 Dec; 54(12):2087-92. PubMed ID: 24136934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Dosimetry and Biodistribution of
    Meyer C; Dahlbom M; Lindner T; Vauclin S; Mona C; Slavik R; Czernin J; Haberkorn U; Calais J
    J Nucl Med; 2020 Aug; 61(8):1171-1177. PubMed ID: 31836685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution, Dosimetry, and Pharmacokinetics of
    Izquierdo-Garcia D; Désogère P; Fur ML; Shuvaev S; Zhou IY; Ramsay I; Lanuti M; Catalano OA; Catana C; Caravan P; Montesi SB
    J Nucl Med; 2023 May; 64(5):775-781. PubMed ID: 37116909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
    Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
    J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
    Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
    J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined model-based and patient-specific dosimetry for
    Plyku D; Mena E; Rowe SP; Lodge MA; Szabo Z; Cho SY; Pomper MG; Sgouros G; Hobbs RF
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):989-998. PubMed ID: 29460025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.